Overview
Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia
Status:
Unknown status
Unknown status
Trial end date:
2015-03-01
2015-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Severe aplastic anemia (SAA)is characterized by the depletion of hematopoietic precursors associated with life-threatening complications. High-dose cyclophosphamide has been found to yield a complete response (CR) in adults and children with SAA.However, the optimal dosage of cyclophosphamide for patients in childhood remains unclear. So we explore the ideal dosage of cyclophosphamide for the treatment of children with SAA.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Xiaofan ZhuTreatments:
Cyclophosphamide
Cyclosporine
Cyclosporins
Criteria
Inclusion Criteria:- Acquired Childhood Severe Aplastic Anemia (SAA)
Exclusion Criteria:
- not Childhood and Acquired Severe Aplastic Anemia